Background
toxicity, deaths, neuroblastoma, Neuroblastoma
NEUROBLASTOMA, NEUROBLASTOMA, SOLID TUMOR
Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 12–15% of cancer-related deaths in children [A randomized trial has demonstrated that therapy with an anti-GDA long-term, continuous infusion regimen for the anti-GDIn the HR-NBL1/SIOPEN study, where patients with HR-NB were given dinutuximab beta as a short, 8-h infusion with or without IL-2 in addition to isotretinoin, co-administration of IL-2 was found to increase toxicity, without further improving outcomes [Differentiation therapy with isotretinoin has been the standard of care for patients with neuroblastoma for many years, based on the results of a randomized clinical study demonstrating its benefits on EFS [Here, we report the results of a multicenter clinical study investigating the activity and safety of single-agent dinutuximab beta (i.e., without IL-2 or isotretinoin) administered by long-term, continuous infusion in patients with relapsed/refractory HR-NB.